Clinical Trial Update: Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis [Phase 1]

View source ↗

Summary

Phase 1 study by Circassia identified potential biomarkers for their peptide immunotherapy approach to cat allergy through gene array analysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cat Allergy

Drugs mentioned

• Circassia Cat Allergy Peptide Immunotherapy (investigational)

Snippet

Sponsor: Circassia Limited | Conditions: Cat Allergy | Phase 1 | Status: COMPLETED